Initiate at least two new gene therapy programs targeting the liver and CNS
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2022
- Due
- 31 Dec 2022
- Delivered
- August 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we expect to initiate at least two new gene therapy programs targeting the liver and CNS during the year”
What we found
Evidence strength A What the grades mean
The company initiated IND-enabling GLP toxicology studies for two new gene therapy programs, AMT-260 (CNS) and AMT-191 (liver/Fabry disease), during 2022, fulfilling the commitment.
-
A uniQure N.V. 10-K filed 2023-02-27
“In July and August 2022, respectively, we initiated Investigational New Drug-enabling (“IND-enabling”), Good Laboratory Practice (“GLP”) toxicology studies in non-human primates for our gene therapy candidates in rTLE and Fabry disease.” ✓ confirmed on the page
-
A uniQure N.V. 10-Q filed 2023-05-09
“In the third quarter of 2022, we initiated a Good Laboratory Practices (“GLP”) toxicology study in non-human primates for AMT-260, a gene therapy product candidate for the treatment of refractory temporal lobe epilepsy (“rTLE”).” ✓ confirmed on the page
Market reaction: the shares moved +8.2% against the S&P 500 over the three sessions around the disclosure (24 Feb 2023 to 1 Mar 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- two new gene therapy programs
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-QURE-001793 · Corrections policy